Abstract：
Although important, clinically significant liver fibrosis is often overlooked in the general population. We aimed to examine the prevalence of clinically significant liver fibrosis using noninvasive tests (NITs) in the general population.
We collected data from four databases (MEDLINE, Embase, Cochrane Library, and KoreaMed) from inception to June 13, 2023. Original articles reporting the prevalence of clinically significant liver fibrosis in the general population were included. The Stata metaprop function was used to obtain the pooled prevalence of liver fibrosis with NITs in the general population.
We screened 6,429 articles and included 45 eligible studies that reported the prevalence of clinically significant liver fibrosis in the general population. The prevalence of advanced liver fibrosis, using the high probability cutoff of the fibrosis-4 (FIB-4) index, was 2.3% (95% confidence interval [CI], 1.2-3.7%). The prevalence of significant liver fibrosis, advanced liver fibrosis, and liver cirrhosis, assessed using vibration-controlled transient elastography (VCTE) among the general population, was 7.3% (95% CI, 5.9-8.8%), 3.5% (95% CI, 2.7-4.5), and 1.2% (95% CI, 0.8-1.8%), respectively. Region-based subgroup analysis revealed that the highest prevalence of advanced fibrosis using the high probability cutoff of the FIB-4 index was observed in the American region. Furthermore, the American region exhibits the highest prevalence of significant liver fibrosis, advanced liver fibrosis, and liver cirrhosis, using VCTE.
Previously undiagnosed clinically significant liver fibrosis is found in the general population through NITs. Future research is necessary to stratify the risk in the general population.
We collected data from four databases (MEDLINE, Embase, Cochrane Library, and KoreaMed) from inception to June 13, 2023. Original articles reporting the prevalence of clinically significant liver fibrosis in the general population were included. The Stata metaprop function was used to obtain the pooled prevalence of liver fibrosis with NITs in the general population.
We screened 6,429 articles and included 45 eligible studies that reported the prevalence of clinically significant liver fibrosis in the general population. The prevalence of advanced liver fibrosis, using the high probability cutoff of the fibrosis-4 (FIB-4) index, was 2.3% (95% confidence interval [CI], 1.2-3.7%). The prevalence of significant liver fibrosis, advanced liver fibrosis, and liver cirrhosis, assessed using vibration-controlled transient elastography (VCTE) among the general population, was 7.3% (95% CI, 5.9-8.8%), 3.5% (95% CI, 2.7-4.5), and 1.2% (95% CI, 0.8-1.8%), respectively. Region-based subgroup analysis revealed that the highest prevalence of advanced fibrosis using the high probability cutoff of the FIB-4 index was observed in the American region. Furthermore, the American region exhibits the highest prevalence of significant liver fibrosis, advanced liver fibrosis, and liver cirrhosis, using VCTE.
Previously undiagnosed clinically significant liver fibrosis is found in the general population through NITs. Future research is necessary to stratify the risk in the general population.
摘要：
■虽然重要,临床上显著的肝纤维化在一般人群中经常被忽视。我们的目的是使用非侵入性测试（NIT）在一般人群中检查临床上显着的肝纤维化的患病率。
■我们从四个数据库（MEDLINE，Embase,科克伦图书馆,和KoreaMed)从成立到2023年6月13日。报告在一般人群中有临床意义的肝纤维化的患病率的原始文章被包括在内。Statametaprop功能用于获得普通人群中NIT合并肝纤维化的患病率。
■我们筛选了6,429篇文章，并纳入了45项符合条件的研究，这些研究报告了普通人群中临床上显着的肝纤维化的患病率。晚期肝纤维化的患病率，使用纤维化-4(FIB-4)指数的高概率截止值，为2.3%(95%置信区间[CI]，1.2-3.7%）。显著肝纤维化的患病率，晚期肝纤维化，肝硬化,在一般人群中使用振动控制瞬时弹性成像(VCTE)进行评估，为7.3%（95%CI，5.9-8.8%），3.5%（95%CI，2.7-4.5），和1.2%（95%CI，0.8-1.8%），分别。基于区域的亚组分析显示，使用FIB-4指数的高概率截止，在美洲地区观察到晚期纤维化的最高患病率。此外，美洲地区表现出最高的患病率显著肝纤维化，晚期肝纤维化，肝硬化,使用VCTE。
■通过NIT在普通人群中发现了先前未诊断的临床显着肝纤维化。未来的研究有必要对普通人群的风险进行分层。
■我们从四个数据库（MEDLINE，Embase,科克伦图书馆,和KoreaMed)从成立到2023年6月13日。报告在一般人群中有临床意义的肝纤维化的患病率的原始文章被包括在内。Statametaprop功能用于获得普通人群中NIT合并肝纤维化的患病率。
■我们筛选了6,429篇文章，并纳入了45项符合条件的研究，这些研究报告了普通人群中临床上显着的肝纤维化的患病率。晚期肝纤维化的患病率，使用纤维化-4(FIB-4)指数的高概率截止值，为2.3%(95%置信区间[CI]，1.2-3.7%）。显著肝纤维化的患病率，晚期肝纤维化，肝硬化,在一般人群中使用振动控制瞬时弹性成像(VCTE)进行评估，为7.3%（95%CI，5.9-8.8%），3.5%（95%CI，2.7-4.5），和1.2%（95%CI，0.8-1.8%），分别。基于区域的亚组分析显示，使用FIB-4指数的高概率截止，在美洲地区观察到晚期纤维化的最高患病率。此外，美洲地区表现出最高的患病率显著肝纤维化，晚期肝纤维化，肝硬化,使用VCTE。
■通过NIT在普通人群中发现了先前未诊断的临床显着肝纤维化。未来的研究有必要对普通人群的风险进行分层。
